Tonix Pharmaceuticals to Host Posttraumatic Stress Disorder (PTSD) Awareness Day
October 19 2016 - 7:00AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is
developing a next-generation treatment for PTSD, announced today
that it will host an educational event featuring prominent academic
physicians to review issues related to understanding and treating
PTSD on October 26, 2016 in New York, NY.
This PTSD Awareness Day will feature
presentations by Jonathan R.T. Davidson, M.D., professor of
Psychiatry and Behavioral Sciences and former Director of the
Anxiety and Traumatic Stress Program at Duke University Medical
Center, and Thomas A. Mellman, M.D., Professor of Psychiatry and
the Director of the Center for Clinical & Translational Science
and the Sleep Stress Program at Howard University Medical Center.
In addition, Tonix’s president and chief executive officer, Seth
Lederman M.D., and chief medical officer, Gregory Sullivan, M.D.,
will provide a corporate update and review of Tonix’s PTSD clinical
program.
Tonix recently held a successful end-of-phase 2
meeting with the U.S. Food and Drug Administration (FDA) based on
positive data from its randomized, double-blind, placebo-controlled
Phase 2 AtEase clinical trial evaluating TNX-102 SL
(cyclobenzaprine HCl sublingual tablets) in military-related
PTSD.
Event: |
|
PTSD Awareness Day |
Date: |
|
Wednesday, October 26,
2016 |
Time: |
|
11:00 am - 2:00 pm (Eastern
Time) |
Location: |
|
Omni Berkshire Hotel -
Juilliard Room, New York, NY |
A live webcast and subsequent replay of the
event will be available on Tonix’s website. To access the webcast,
please visit the Events tab of the Investor Relations section of
Tonix’s website at www.tonixpharma.com.
TNX-102 SL (cyclobenzaprine HCl sublingual
tablets) is an Investigational New Drug and has not been approved
for any indication.
About Tonix Pharmaceuticals Holding
Corp.
Tonix is developing next-generation medicines
for common disorders of the central nervous system, with its lead
program focusing on PTSD. This disorder is characterized by chronic
disability, inadequate treatment options, high utilization of
healthcare services, and significant economic burden. This press
release and further information about Tonix can be found at
www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
substantial competition; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of
government or third party payor reimbursement; limited research and
development efforts and dependence upon third parties; and risks
related to failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations. As with any pharmaceutical
under development, there are significant risks in the development,
regulatory approval and commercialization of new products. Tonix
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in the Annual Report on Form 10-K for the year ended
December 31, 2015, as filed with the Securities and Exchange
Commission (the “SEC”) on March 3, 2016, and future periodic
reports filed with the SEC on or after the date hereof. All of
Tonix's forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date hereof.
Contacts
Jessica Smiley
Investor Relations
investor.relations@tonixpharma.com
(212) 980-9155 x185
Edison Advisors (investors)
Tirth Patel
tpatel@edisongroup.com
(646) 653-7035
Dian Griesel Int’l (media)
Susan Forman / Laura Radocaj
sforman@dgicomm.com
iradocaj@dgicomm.com
(212) 825-3210
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Oct 2023 to Oct 2024